Selvita Group Received a GMP Certificate
News Feb 19, 2014
Selvita has received a GMP certificate.
On February 11 2014, after positive inspection conducted by the Main Pharmaceutical Inspectorate (the competent authority of Poland granting GMP certificates), BioCentrum, a part of Selvita Group received a certificate of compliance with the principles of Good Manufacturing Practice (GMP).
GMP certificate was granted based on positive results of GMP inspection conducted on 19-20 November 2013. The range of GMP certificate covers all services offered by the Analytical Laboratory, including physical and chemical testing in quality control of the pharmaceutical products.
Positive results of the GMP inspection confirmed that Selvita complies with the standards and requirements of the GMP in its routine activities and all studies conducted in Selvita Group, are planned, performed, monitored, and reported in accordance with the international quality standards established by the pharmaceutical industry.
"GMP certification is an extremely important event in the Selvita’s development. Obtaining the GMP certificate proves that the quality of research is one of the strategic objectives of our company. The GMP and GLP certificates confirm that our laboratories are working according to the highest worldwide quality standards. Thanks to the GLP/GMP quality system our company is more recognizable in the world, and the results generated by our scientists are credible and accepted by the registration authorities in other countries" - said Dr. Miłosz Gruca, Director of Research and Development, Board Member of BioCentrum Sp. z o.o.
Selvita Group Analytical Laboratory joined the elite group of five Polish laboratories certified in both GMP and GLP.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE